JP2019534446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534446A5 JP2019534446A5 JP2019514825A JP2019514825A JP2019534446A5 JP 2019534446 A5 JP2019534446 A5 JP 2019534446A5 JP 2019514825 A JP2019514825 A JP 2019514825A JP 2019514825 A JP2019514825 A JP 2019514825A JP 2019534446 A5 JP2019534446 A5 JP 2019534446A5
- Authority
- JP
- Japan
- Prior art keywords
- metabolite
- subject
- acid
- biomarker
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017898A JP7451791B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2024034012A JP7692508B2 (ja) | 2016-09-16 | 2024-03-06 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2025092519A JP2025124816A (ja) | 2016-09-16 | 2025-06-03 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395770P | 2016-09-16 | 2016-09-16 | |
| US62/395,770 | 2016-09-16 | ||
| US201762518367P | 2017-06-12 | 2017-06-12 | |
| US62/518,367 | 2017-06-12 | ||
| PCT/US2017/051755 WO2018053247A1 (en) | 2016-09-16 | 2017-09-15 | Metabolite biomarkers for diseases associated with the contact activation system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017898A Division JP7451791B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534446A JP2019534446A (ja) | 2019-11-28 |
| JP2019534446A5 true JP2019534446A5 (enExample) | 2020-10-22 |
| JP7225090B2 JP7225090B2 (ja) | 2023-02-20 |
Family
ID=59974882
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514825A Active JP7225090B2 (ja) | 2016-09-16 | 2017-09-15 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2023017898A Active JP7451791B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2024034012A Active JP7692508B2 (ja) | 2016-09-16 | 2024-03-06 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2025092519A Pending JP2025124816A (ja) | 2016-09-16 | 2025-06-03 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017898A Active JP7451791B2 (ja) | 2016-09-16 | 2023-02-08 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2024034012A Active JP7692508B2 (ja) | 2016-09-16 | 2024-03-06 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
| JP2025092519A Pending JP2025124816A (ja) | 2016-09-16 | 2025-06-03 | 接触活性化系に関連する疾患の代謝物バイオマーカー |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11340237B2 (enExample) |
| EP (1) | EP3513197A1 (enExample) |
| JP (4) | JP7225090B2 (enExample) |
| KR (3) | KR20250030022A (enExample) |
| CN (2) | CN117169508A (enExample) |
| AU (1) | AU2017325986B2 (enExample) |
| BR (1) | BR112019005167A2 (enExample) |
| CA (1) | CA3037157A1 (enExample) |
| CO (1) | CO2019002607A2 (enExample) |
| IL (2) | IL265199B2 (enExample) |
| MX (2) | MX2019002918A (enExample) |
| WO (1) | WO2018053247A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011204349C1 (en) | 2010-01-06 | 2017-02-16 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| ES2856076T3 (es) * | 2014-01-21 | 2021-09-27 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario |
| US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| MX2019002932A (es) | 2016-09-16 | 2019-07-15 | Dyax Corp | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
| EP3513197A1 (en) | 2016-09-16 | 2019-07-24 | Dyax Corp. | Metabolite biomarkers for diseases associated with the contact activation system |
| EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
| CA3144694A1 (en) | 2019-07-25 | 2021-01-28 | Jose A. Horcajadas | Identification of viable human embryos |
| CN110514772A (zh) * | 2019-08-09 | 2019-11-29 | 中国医学科学院基础医学研究所 | 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用 |
| EP4126219A2 (en) * | 2020-04-04 | 2023-02-08 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
| CN113495137A (zh) * | 2021-06-29 | 2021-10-12 | 江苏省中医院 | 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用 |
| CN117310059B (zh) * | 2023-11-30 | 2024-02-02 | 中国人民解放军总医院 | 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739355B1 (en) | 1994-01-11 | 2004-09-08 | Dyax Corporation | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| US7064107B2 (en) | 2002-06-07 | 2006-06-20 | Dyax Corp. | Prevention and reduction of blood loss |
| EP1711828A2 (en) | 2004-01-28 | 2006-10-18 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2) |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| US20070218519A1 (en) | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US7625944B2 (en) * | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| US20080031816A1 (en) | 2006-08-03 | 2008-02-07 | Charles Keller | Methods and compositions for identifying biomarkers |
| WO2008046517A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Ctgf as a biomarker, therapeutic and diagnostic target |
| WO2008046510A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Fn1 as a biomarker, therapeutic and diagnostic target |
| WO2008046528A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Npr3 as a biomarker, therapeutic and diagnostic target |
| WO2008046512A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | Prss23 as a biomarker, therapeutic and diagnostic target |
| WO2008046508A1 (en) | 2006-10-16 | 2008-04-24 | Bayer Healthcare Ag | Tgfb2 as a biomarker, therapeutic and diagnostic target |
| US20100081136A1 (en) | 2006-10-16 | 2010-04-01 | Stefan Golz | Crtac as a biomarker, therapeutic and diagnostic target |
| US8088584B2 (en) | 2006-10-16 | 2012-01-03 | Bayer Schering Pharma Aktiengesellschaft | LTBP2 as a biomarker and diagnostic target |
| FR2914066B1 (fr) | 2007-03-20 | 2009-05-22 | Polyintell Sarl | Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant |
| JP5564491B2 (ja) * | 2008-04-29 | 2014-07-30 | サイケメディクス コーポレイション | 固相多分析物アッセイ法 |
| WO2010045180A1 (en) * | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
| WO2011019072A1 (ja) * | 2009-08-12 | 2011-02-17 | ヒューマン・メタボローム・テクノロジーズ株式会社 | うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体 |
| US20110098993A1 (en) | 2009-10-27 | 2011-04-28 | Anaxomics Biotech Sl. | Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data |
| WO2011053831A1 (en) | 2009-10-30 | 2011-05-05 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| ES2532006T3 (es) | 2009-11-20 | 2015-03-23 | Pharnext | Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth |
| AU2011204349C1 (en) | 2010-01-06 | 2017-02-16 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| CA2793735A1 (en) | 2010-03-23 | 2011-09-29 | M. Daniel Raftery | Early detection of recurrent breast cancer using metabolite profiling |
| US20120040383A1 (en) | 2010-08-12 | 2012-02-16 | Wei Jia | Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer |
| WO2012094587A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| JP5986440B2 (ja) | 2012-07-05 | 2016-09-06 | 国立医薬品食品衛生研究所長 | アルツハイマー病の発症を予測する方法 |
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| US20140086825A1 (en) | 2012-09-24 | 2014-03-27 | William J. McFaul | Methods and kits for assessing, modulating and treating substances affecting bodily processes |
| SMT201900204T1 (it) | 2013-01-20 | 2019-05-10 | Dyax Corp | Valutazione, saggi e trattamento di disturbi mediati da pkal |
| IL273688B2 (en) | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016514141A (ja) | 2013-03-14 | 2016-05-19 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Ｂ２−ブラジキニン受容体媒介の血管浮腫の治療方法 |
| SG11201506875YA (en) * | 2013-03-15 | 2015-09-29 | Intrexon Corp | Boron-containing diacylhydrazines |
| KR20250066486A (ko) * | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| EP2884282A1 (en) * | 2013-12-13 | 2015-06-17 | CONARIS research institute AG | Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency |
| AU2015243857A1 (en) | 2014-04-08 | 2016-10-20 | Metabolon, Inc. | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment |
| TWI614501B (zh) | 2014-09-22 | 2018-02-11 | National Health Research Institutes | ５-甲氧基色胺酸作為發炎疾病診斷試劑之用途 |
| AU2016243160B2 (en) * | 2015-03-30 | 2022-02-24 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| BR112018002742B1 (pt) | 2015-08-13 | 2023-05-16 | Takeda Pharmaceutical Company Limited | Tubo de coleta de sangue evacuado, método para a avaliação do nível endógeno de ativação do sistema de contato em um sujeito, método para a avaliação do nível de um fármaco visando o sistema de contato em um sujeito e método para a avaliação da imunogenicidade de um fármaco visando o sistema de contato |
| JP6570472B2 (ja) | 2016-03-30 | 2019-09-04 | 株式会社マンダム | 毛髪の損傷の評価方法 |
| EP3513197A1 (en) | 2016-09-16 | 2019-07-24 | Dyax Corp. | Metabolite biomarkers for diseases associated with the contact activation system |
| MX2019002932A (es) | 2016-09-16 | 2019-07-15 | Dyax Corp | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. |
| BR112019005172A2 (pt) | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
-
2017
- 2017-09-15 EP EP17777137.5A patent/EP3513197A1/en active Pending
- 2017-09-15 IL IL265199A patent/IL265199B2/en unknown
- 2017-09-15 CA CA3037157A patent/CA3037157A1/en active Pending
- 2017-09-15 KR KR1020257006143A patent/KR20250030022A/ko active Pending
- 2017-09-15 KR KR1020227038426A patent/KR102775437B1/ko active Active
- 2017-09-15 KR KR1020197010802A patent/KR102464380B1/ko active Active
- 2017-09-15 MX MX2019002918A patent/MX2019002918A/es unknown
- 2017-09-15 IL IL314752A patent/IL314752A/en unknown
- 2017-09-15 AU AU2017325986A patent/AU2017325986B2/en active Active
- 2017-09-15 JP JP2019514825A patent/JP7225090B2/ja active Active
- 2017-09-15 BR BR112019005167-8A patent/BR112019005167A2/pt active IP Right Grant
- 2017-09-15 CN CN202310782203.XA patent/CN117169508A/zh active Pending
- 2017-09-15 US US16/333,101 patent/US11340237B2/en active Active
- 2017-09-15 WO PCT/US2017/051755 patent/WO2018053247A1/en not_active Ceased
- 2017-09-15 CN CN201780057052.4A patent/CN109716137B/zh active Active
-
2019
- 2019-03-13 MX MX2024004195A patent/MX2024004195A/es unknown
- 2019-03-21 CO CONC2019/0002607A patent/CO2019002607A2/es unknown
-
2022
- 2022-04-25 US US17/728,285 patent/US12188948B2/en active Active
-
2023
- 2023-02-08 JP JP2023017898A patent/JP7451791B2/ja active Active
-
2024
- 2024-03-06 JP JP2024034012A patent/JP7692508B2/ja active Active
- 2024-11-26 US US18/960,119 patent/US20250199014A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092519A patent/JP2025124816A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534446A5 (enExample) | ||
| JP2023058612A5 (enExample) | ||
| Senthong et al. | Plasma trimethylamine N-oxide, a gut microbe–generated phosphatidylcholine metabolite, is associated with atherosclerotic burden | |
| Clifford et al. | FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption | |
| Walther et al. | Lipidomics in major depressive disorder | |
| Yu et al. | Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics | |
| Howcroft et al. | The role of inflammation in age-related disease | |
| JP2018502286A5 (enExample) | ||
| Carcaillon et al. | High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women | |
| Hu et al. | Toll-like receptor 4 is a master regulator for colorectal cancer growth under high-fat diet by programming cancer metabolism | |
| JP7225090B2 (ja) | 接触活性化系に関連する疾患の代謝物バイオマーカー | |
| Mathew et al. | Metabolomics of Ramadan fasting: an opportunity for the controlled study of physiological responses to food intake | |
| Misiak et al. | Decreased use of active coping styles contributes to elevated allostatic load index in first-episode psychosis | |
| Biemann et al. | Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial | |
| Gårevik et al. | Single dose testosterone increases total cholesterol levels and induces the expression of HMG CoA Reductase | |
| Di Venere et al. | Advances in the analysis of “less‐conventional” human body fluids: An overview of the CE‐and HPLC‐MS applications in the years 2015–2017 | |
| Lee et al. | Identification of altered metabolic pathways during disease progression in EAE mice via metabolomics and lipidomics | |
| Akanuma et al. | Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood–brain barrier | |
| Taut et al. | NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes | |
| Yusri et al. | Towards healthy longevity: comprehensive insights from molecular targets and biomarkers to biological clocks | |
| JP2016526167A5 (enExample) | ||
| Cruciani et al. | Redox lipidomics and adductomics-Advanced analytical strategies to study oxidized lipids and lipid-protein adducts | |
| Gart et al. | Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr−/−. Leiden mice | |
| Chen et al. | Comparison of biliary protein spectrum in gallstone patients with obesity and those with normal body weight | |
| JP2017019776A5 (enExample) |